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Vitamin D deficiency is frequent during the winter and occurs throughout the year in the
elderly or patients suffering from autoimmune diseases. The objective of this study was to
evaluate the pharmacokinetic properties of oral supplementation versus a single intramus-
cular injection of cholecalciferol in healthy individuals.
Research design and methods
Up to 8,000 I.U. oral cholecalciferol was administered daily for 84 days in a 4 week dose-
escalation setting to vitamin D deficient individuals. In another cohort, a single intramuscular
injection of 100,000 I.U. cholecalciferol was given. In both cohorts, individuals without vita-
min D intake served as the comparison group. 25-hydroxyvitamin D (25(OH)D) concentra-
tions were measured in all individuals at defined time points throughout the studies.
Results
The mean 25(OH)D serum concentration increased significantly after oral cholecalciferol
intake compared to the control group (day 28: 83.4 nmol/l and 42.5 nmol/l; day 56: 127.4
nmol/l and 37.3 nmol/l; day 84: 159.7 nmol/l and 30.0 nmol/l). In individuals receiving
100,000 I.U. cholecalciferol intramuscular, the mean 25(OH)D serum concentration peaked
after 4 weeks measuring 70.9 nmol/l compared to 32.7 nmol/l in the placebo group (p =
0.002). The increase of 25(OH)D serum concentrations after 28 days was comparable
between both routes of administration (p = 0.264).
Conclusions
Oral and intramuscular cholecalciferol supplementation effectively increased serum 25(OH)
D concentrations.
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Introduction
Vitamin D deficiency is a frequent medical condition, not only in the elderly but also in young
adults, depending on lifestyle factors [1–3]. The major sources of vitamin D (chemical chole-
calciferol) are the cutaneous synthesis upon sunlight exposure and, to a minor extent, dietary
intake. The active form of vitamin D is a fat-soluble seco-steroid hormone [4]. When synthe-
sized in the skin or provided through the diet, vitamin D is biologically inactive. It is hydroxyl-
ated twice into (a) the storage metabolite 25-hydroxyvitmamin D (25(OH)D) and (b) the
biologically active metabolite 1.25-dihydroxyvitamin D (calcitriol) [5]. The 25(OH)D has a cir-
culating half-life of 3 weeks [6] and is commonly used to determine the vitamin D status [7].
Calcitriol is known to regulate intestinal calcium absorption, serum calcium and phosphate
homeostasis, bone mineralization and immune regulation [8, 9]. The optimal dosage, fre-
quency and route of administration to reach sufficient vitamin D levels in the blood (25(OH)
D> 50 nmol/l) are still controversially discussed [6]. Different administration routes are used
to increase systemic vitamin D concentrations, e.g. oral and intramuscular (i.m.). The oral sup-
plementation is the first-line vitamin D deficiency treatment. If 25(OH)D serum concentra-
tions do not increase after adequate substitution, an i.m. injection with cholecalciferol is
indicated. The possible reasons for oral vitamin D resistance include malabsorption, liver—or
kidney failure and obesity [10]. Single, large vitamin D doses were studied without determin-
ing the optimal dosage, or route of administration. Until now no general recommendation is
available.
This study had been designed to assess peak vitamin D concentrations after a 100,000 I.U.
single dose application in comparison to monthly increasing oral cholecalciferol substitution.
Patients and Methods
Oral vitamin D supplementation
In the first cohort, 43 healthy subjects between the age of 18 and 60 years were enrolled in an
open label study (Table 1) [11]. The exclusion criteria were a lack of consent, incompliance,
scheduled sun tanning or UV exposure, a positive history of sarcoidosis, hypercalcemia, serum
creatinine concentration > 1 mg/dl, nephrolithiasis, pregnancy and lactation, diseases of the
cardiovascular system, cancer, malabsorption or chronic infection. Individuals of the vitamin
D group (n = 25) received monthly increasing doses of 2,000 I.U. (50μg, week 1 to 4), 4,000 I.
U. (100μg, week 5 to 8) and 8,000 I.U. (200μg, week 9 to 12) of cholecalciferol per day. Healthy
individuals without vitamin D intake served as a control group (n = 18). Both study groups
were comparable with respect to age, gender, and basal serum 25(OH)D concentrations
(Table 1). Blood samples for serum analysis were drawn at baseline and after 4, 8 and 12
weeks. Serum 25(OH)D levels were measured using the serum 25(OH)D ELISA kit (IDS Ham-
burg, Germany).
Table 1. Baseline characteristics of the patients with oral and intramuscular vitamin D supplementation. Values given as mean and standard devia-
tion; p-values calculated using Students-T-Test, n.s. = not significant, n.a. = not applicable.
Study oral oral p-value i.m. i.m. p-value
Characteristics Vitamin D Placebo n.a. Vitamin D Placebo n.a.
Number (n) 25 18 n.a. 12 6 n.a.
Sex (f /m) 9 / 16 7 / 11 n.a. 8 / 4 4 / 2 n.a.
Age (years) 33.4 ± 6.6 31.7 ± 5.2 n.s. 34.9 ± 9.1 36 ± 13 n.s.
25(OH)D (nmol/l) 40.0 ± 12.9 46.3 ± 14.0 n.s. 33.0 ± 8.5 42.9 ± 6.1 n.s.
Body mass index (BMI) 23.2 ± 3.3 23.0 ± 3.5 n.s. 22.2 ± 3.2 22.3 ± 3.6 n.s.
doi:10.1371/journal.pone.0169620.t001
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Intramuscular vitamin D supplementation
The second cohort of 18 healthy vitamin D deficient (<55 nmol/l as per protocol) subjects was
randomized in a placebo-controlled pilot study (Table 1). Twelve women and 6 men between
18 and 60 years of age were recruited and enrolled if the inclusion and exclusion criteria as
mentioned above were met. The cohorts randomization into vitamin D or placebo groups
(ratio 2:1) performed by assigning the individuals in the order of appearance to a gender-spe-
cific list generated by an external pharmacist (Charite´ Berlin, Germany) (Fig 1).
Fig 1. Consort flow chart. I.m. vitamin D application.
doi:10.1371/journal.pone.0169620.g001
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The study medication was applied by an unblinded staff member to 12 individuals receiving
an i.m. injection with 100,000 I.U. cholecalciferol (D3-Vicotrat1, Heyl Germany) and 6 sub-
jects receiving a sodium chloride injection (Braun Melsungen, Germany, Placebo).
Both study groups were comparable according to age, ethnicity, weight and height
(Table 1). Pharmacokinetics were monitored by 25(OH)D serum concentrations which were
measured by our laboratory (Labor Berlin—Charite´ Vivantes GmbH).
Both clinical studies were approved by the ethical committee (Ethik-Kommission des
Landes Berlin) and conducted according to the principles expressed in the Helsinki Declara-
tion. A written and oral informed consent had been obtained from the participants before any
investigation was performed. Both studies were performed during the winter months (October
to March).
Statistical Methods
Statistical evaluations were performed with GraphPad Prism 5 (GraphPad Software, Inc., CA,
USA) and SPSS21 (IBM, NY, USA). Normal distribution was tested by the Kolmogorov-Smir-
nov test. The data for the serum 25(OH)D concentrations were analysed and values are shown
as mean ± SD (standard deviation). 25(OH)D increase from the baseline visit to the 28th day
between the oral vitamin D and the i.m. verum group was analysed using a two-sided t-test for
independent groups. P-values (p) 0.05 were considered to be statistically significant. Effect
size (dCohen) and confidence intervals (CI) were calculated as described elsewhere [12].
Serum 25(OH)D increase inter-group comparison was tested with Whitney-Mann-U-Test.
Results
Oral vitamin D intake efficiently increased serum 25(OH)D
concentrations, but not in the control group
Vitamin D deficiency is defined as a serum 25(OH)D level of less than 50 nmol/l(10), based on
the recommendations of the Institute of Medicine (IOM) [13]. Others and our group observed
a seasonal variation in serum 25(OH)D concentrations in the latitude of Berlin, Germany
(approximately 52˚N) [14]. During the winter months, serum 25(OH)D levels are significantly
lower due to an insufficient amount of UV-light (October-March: UV-index 2) and lacking
skin exposure by low temperatures [15], which eliminates the bias of UV-mediated vitamin D
synthesis.
As expected, the baseline 25(OH)D serum concentrations in the control group without vita-
min D intake decreased during the study period (mean: day 0 = 46.3 nmol/l, day 28 = 42.5
nmol/l, day 56 = 37.3 nmol/l, day 84 = 30.0; p<0.001compared to the baseline (Table 2).
In the vitamin D group, the 25(OH)D serum concentrations increased from a mean base-
line level of 40.0 nmol/l during 4-week intervals with the oral intake of 2,000 I.U. cholecalcif-
erol per day (total dose of 56,000 I.U.) to 83.4 nmol/l (p<0.001, dCohen compared to
Table 2. Serum 25(OH)D concentrations during oral vitamin D supplementation. Data shown as mean ± SD, number of individuals, n; p-values calcu-
lated by Students-T-Test, effect size calculated by dCohen and 95% confidence intervals. Not applicable = n.a.
Day of the study (daily vit.D in I.U.) Vitamin D group Control group p-value Effect size dCohen (CI 95%)
0 40.0 ± 12.9, n = 25 46.3 ± 14.0, n = 17 0.23 n.a.
28 (2000 I.U) 83.4 ± 14.5, n = 25 42.5 ± 13.4, n = 18 < 0.001 2.93 (2.04–3.82)
56 (4000 I.U) 127.4 ± 38.1, n = 25 37.3 ± 14.6, n = 18 < 0.001 3.00 (2.10–3.90)
84 (8000 I.U) 159.7 ± 28.7, n = 10 30.0 ± 11.5, n = 18 < 0.001 6.59 (4.63–8.56)
84 (vit.D stopped at day 56) 96.1 ± 20.1, n = 15 30.0 ± 11.5, n = 18 < 0.001 4.19 (2.95–5.43)
doi:10.1371/journal.pone.0169620.t002
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control = 2.93), after an additional 4 week with 4.000 I.U. cholecalciferol per day (total 112,000
I.U.) to 127.4 nmol/l (p<0.001, dCohen = 3.00), and finally after the last 4 week with 8,000 I.U.
per day (total 224,000 I.U.) to 159.7 nmol/l (p<0.001, dCohen = 6.59, n = 10). In the subgroup
reaching up to 110.0 nmol/l serum 25(OH)D at day 56, vitamin D intake was stopped to pre-
vent potentially toxic levels and decreased values were determined on day 84 (96.1 nmol/l
(p<0.001, dCohen = 4.19, n = 15).
Intramuscular vitamin D supplementation significantly increased serum 25(OH)D concen-
trations for 3 months, in contrast to placebo.
25(OH)D serum concentration was measured before the single cholecalciferol injection of
100,000 I.U. on day 3, day 7, day 14, day 21, day 28, day 42, day 56 and day 84 after the admin-
istration (Table 3).
The baseline 25(OH)D serum concentrations were comparable in the vitamin D group
measuring 32.2 nmol/l ± 8.9 nmol/l (range: <12.5 nmol/l to 49.7 nmol/l) and in the placebo
group measuring 42.9 nmol/l ± 6.7 nmol/l (range: 38.3 nmol/l to 55.1 nmol/l). 3 days after vita-
min D administration, the serum concentration increased by 16.8 nmol/l in the vitamin D
group. After 7 days, 25(OH)D serum concentrations increased to a mean of 57.8 nmol/l ± 13.8
nmol/l in the vitamin D group, whereas it decreased to a mean of 39.8 nmol/l in the placebo
treated group (Table 3). On day 28, the 25(OH)D serum concentrations increased significantly
and peaked in the vitamin D treated group with a mean of 70.9 nmol/l and remained low in
the placebo treated individuals (mean 37.0 nmol/l, p = 0.002). After 2 months, 25(OH)D
serum concentrations was again decreased to 58.0 nmol/l in the vitamin D group and 32.7
nmol/l in the placebo treated group. Finally, 3 months after the injection, with the beginning
of the UV rich season 25(OH)D (April, UV-index 4–5), serum concentrations increased in the
vitamin D (75.2 nmol/l) as well as in the placebo group (49.7 nmol/l).
Influencing factors and tolerability
There were no correlations of the 25(OH)D serum levels between gender, age or body mass
index (BMI). No side effects or adverse events related to the investigational drug were reported
throughout both clinical studies. The serum calcium and phosphate levels were monitored for
safety purposes and remained stable throughout the study (data not shown). 5 individuals
showed a mild hypophosphatemia which was not related to vitamin D supplementation.
A comparable increase in serum 25(OH)D concentration upon 4 weeks of oral and intra-
muscular supplementation.
25(OH)D serum concentrations increased significantly upon both, the oral and i.m. route
of administration (Fig 2).
Next, we compared the 25(OH)D serum concentration increase from the baseline to the
day 28 between oral and i.m. supplementation (Fig 3).
Table 3. Serum 25(OH)D concentrations during intramuscular vitamin D supplementation. Data shown as mean ± SD, number of individuals, n; p-val-
ues calculated by Students-T-Test, effect size calculated by dCohen and 95% confidence intervals. Not applicable = n.a.
Days after vit D injection Vitamin D (i.m.) n = 12 Placebo (i.m.) n = 6 p-value Effect size dCohen (CI 95%)
0 32.2 ± 8.9 42.9 ± 6.7 0.03 n.a.
7 57.8 ± 13.8 39.8 ± 8.4 0.01 1.50 (0.41–2.60)
28 70.9 ± 21.6 37.0 ± 7.1 0.002 1.92 (0.76–3.09)
56 58.0 ± 16.7 32.7 ± 8.7 0.004 1.77 (0.63–2.91)
84 75.2 ± 19.9 49.7 ± 9.1 0.009 1.55 (0.44–2.65)
doi:10.1371/journal.pone.0169620.t003
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The mean 25(OH)D increase in the oral group measured 44.2 nmol/l ± 13.1 nmol/l and the
i.m. group was 37.2 nmol/l ± 19.6 nmol/l. Statistical analysis revealed no significant difference
in 25(OH)D increase between oral and i.m. supplementation groups (Fig 3, p = 0.264).
Discussion
Vitamin D deficiency is prevalent in the population of higher latitudes [10, 16, 17]. Several treat-
ment approaches using oral and injectable vitamin D have been proposed in the literature for
vitamin D deficiency correction. It has been shown that daily oral [18–20] or a single high dose
[21, 22] supplementation effectively restores the vitamin D status. Upon certain circumstances,
e.g. limited intestinal resorption, i.m. injections are the preferred route of administration [23,
24]. Our data shows that one month after an i.m. injection of 100,000 I.U. cholecalciferol the
25(OH)D serum concentrations increased to a mean of 70.9 nmol/l. As approximately 50% of
the individuals still remained vitamin D deficient after a single dose, the data suggest that a
higher dose is most likely more effective and probably safe [1, 23, 25]. Only by future prospec-
tive randomized clinical trials with different doses given, e.g. 100,000 I.U., 150,000 I.U., 200,000
I.U. or even higher will clarify the optimal dose of i.m. vitamin D supplementation. Otherwise,
analysis of repeated administration of 100,000 I.U, e.g. monthly will contribute to defining an
algorithm that predicts the optimal supplementation intervals. However, as in particular in the
elderly the oral intake of drugs might be diminished and/or in the presence of intestinal malab-
sorption disorders this route might be preferred.
Still, only limited data are available on the effects of oral and i.m. vitamin D supplementa-
tion and their pharmacokinetics. In a previous report, serum 25(OH)D levels gradually
increased in 7 weeks after injection [26]. Here, after 100,000 I.U. i.m. the serum 25(OH)D
Fig 2. Serum 25(OH)D concentration at the baseline and day 28. Serum 25(OH)D was determined at the
baseline and day 28 upon oral and i.m. supplementation.
doi:10.1371/journal.pone.0169620.g002
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concentrations peaked after 4 weeks and decreased in the following 4 weeks. The oral supple-
mentation resulted in a rapid increase in serum 25(OH)D levels, which peaked about 1 week
after first daily dose of 80 μg/kg (3,200 I.U./kg) cholecalciferol [26]. In comparison to i.m.
injection, the increase in serum 25(OH)D levels were more rapid but also more transient after
oral administration of vitamin D, as previously observed [27]. The sustained levels of serum
25(OH)D concentrations can be explained by the vitamin D fat tissue storage capacity with a
slow and gradual release of i.m. administered cholecalciferol [26]. Interestingly, we observed
the maximal increase of 25(OH)D in oral and i.m. group on day 28 upon supplementation.
However, the mean 25(OH)D concentration increase in both groups was comparable. Our
study shows some limitations. First, the open label protocol for oral vitamin D supplementa-
tion. Additionally, the study population included mostly young subjects. Larger cohorts con-
sidering elderly subjects should be analyzed in further randomized clinical trials.
In summary, our results confirm that the oral route of cholecalciferol administration rap-
idly increases 25(OH)D serum levels. However, discontinuing oral supplementation is fol-
lowed by an early and more rapid decrease of 25(OH)D in contrast to the i.m. application.
Conclusions
Administration of vitamin D either by oral or i.m. increased the 25(OH)D serum concen-
trations. Thus, both supplementation routes are relevant in clinical practice. As the
Fig 3. Serum 25(OH)D concentration after oral and i.m. vitamin D supplementation. Comparable
increase of serum 25(OH)D concentration at the baseline and day 28 in the oral and i.m. supplementation
group. Data shown as median, interquartile ranges and overall range with p-value calculated by Whitney-
Mann-U-Test.
doi:10.1371/journal.pone.0169620.g003
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pharmacokinetics depending on the administration route, different treatment protocols
may be required. The data from this study and previous data suggest an oral cholecalciferol
supplementation of 2,000 I.U.– 4,000 I.U. daily from January till March in healthy adults is
sufficient to achieve adequate serum 25(OH)D status. Alternatively, 100,000 I.U. may be
administered i.m. completely free from side effects in individuals with e.g. impaired- gastro-
intestinal resorption or limited compliance.
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